Stay updated with breaking news from Novel protein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A company building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (pathway) has announced a further extension to its series B financing round. ....
Funding advances project development for new facility that will be the first purpose-built commercial precision fermentation plant in the United States. ....
ChickP Going Commercial with Novel Protein USA - English News provided by Share this article Share this article REHOVOT, Israel, Feb. 23, 2021 /PRNewswire/ FoodTech start-up ChickP Protein, Ltd. announces full commercial production of its 90% chickpea isolate. The company is simultaneously expanding its global activities, having kicked-off a venture in the US by sealing a joint market development agreement with Socius Ingredients, Inc. Caption: ChickP Going Commercial with Novel Protein ChickP revved up consistent, stable production capacity to 20 metric tons per day, equating to more than 5,000 metric tons annually of its uniquely concentrated non-GMO, allergen-free chickpea protein isolate. The ingredient is designed to provide protein-infused functionality and a nutritional boost to an array of food and supplement applications, including dairy alternatives, baked products, and gluten-free foods. The company also is actively seeking new opportun ....
CEACAM7 : Novel protein may improve safety of therapy for pancreatic cancer This is an exciting development, said John Marshall, Professor from Queen Mary University of London Saturday January 23, 2021 12:45 PM, IANS London: Researchers have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the team successfully created a CAR T cell therapy a type of immunotherapy that killed pancreatic cancer cells in a pre-clinical model. This is an exciting development, said John Marshall, Professor from Queen Mary University of London. Finding that CEACAM7 allows us to kill pancreatic cancer cells specifically with CAR T cells while having no significant toxicity in non-tumour tissues, gives us hope that this strategy could be effective in the future, Marshall added. ....